A Phase II, Randomized, Open Label Study of Single Dose siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2016
At a glance
- Drugs Antisense K-ras RNA gene therapy (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Silenseed
- 18 Oct 2016 Planned number of patients changed from 124 to 80.
- 18 Oct 2016 Planned End Date changed from 1 Nov 2018 to 1 Jun 2020.
- 18 Oct 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Feb 2019.